United States: Actavis To Acquire Durata Therapeutics, Inc.
Last Updated: October 14 2014

On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23 per share in cash, or approximately $675 million in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE" are achieved. Durata Therapeutics is an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

The WilmerHale team representing Durata Therapeutics includes Corporate Partners Brian Johnson, Jay Bothwick and Joseph Conahan, Senior Associate Chris Barnstable-Brown and Associate Mhairi Collins Immermann, and Tax Partners Kimberly Wethly, Scott Kilgore and Matt Schnall, as well as Senior Associate Ciara Baker.

The complete release with details of the transaction can be found on Durata Therapeutics' site.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By David Gammell
By Jonathan Cedarbaum, D. Reed Freeman, Jr., Alan Schoenfeld, Heather Zachary, Stephanie Simon
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
Font Size: